



## The 14th International Symposium on Myelodysplastic Syndromes

Plenary Session	Interactive Session	Parallel Session	Meet the Expert	Patients Forum	Nurse Program
Social Event	Oral Session	Tito Bastianello and MDS Foundation Young Investigators Award	Industry Sessions	Guided Poster Session	Pharmacist Session



### Wednesday, May 3, 2017

Time	Auditorium 1	Auditorium 2	Auditorium 3	Exhibition Area
12:00 - 14:00		<div style="text-align: center;">  <p>Workshop I: Cytometry</p> <p>Chair: <b>Alberto Orfao</b>, Spain</p> <p>Welcome and Introduction <b>Alberto Orfao</b>, Spain</p> <p>ELN Recommendations on Flow Immuno-Phenotyping in MDS <b>Arjan A. van de Loosdrecht</b>, The Netherlands</p> <p>Normal vs MDS-Associated Phenotypes of CD34+ Precursors <b>Alberto Orfao</b>, Spain</p> <p>Altered Phenotypes of Maturing Neutrophils in MDS <b>Amparo Sempere</b>, Spain</p> <p>Altered Monocytic Maturation in MDS <b>Sergio Matarraz</b>, Spain</p> <p>Multicentric Detection of Dysplastic Erythroblast Phenotypes In MDS: Is There a Need for Standardization? <b>Theresia M. Westers</b>, The Netherlands</p> <p>Case Presentation <b>Alberto Orfao</b>, Spain</p> <p>Final Remarks and Conclusion</p> </div>		

<p>14:00 - 16:00</p>			<p> Workshop II: From Chromosome Banding to NGS - A Diagnostic Approach to MDS</p> <p>Chair: <b>Francesc Solé</b>, Spain</p> <p>Welcome <b>Francesc Solé</b>, Spain</p> <p>Interactive Questions <b>José Cervera</b>, Spain</p> <p>The Best and Worth of: Cytogenetics <b>Detlef Haase</b>, Germany</p> <p>The Best and Worth of: Fish <b>Cristina Mecucci</b>, Italy</p> <p>The Best and Worth of: SNP/CGH Arrays <b>José Cervera</b>, Spain</p> <p>The Best and Worth Of: NGS <b>Rafael Bejar</b>, USA</p> <p>Selected Cases</p> <p>Closing Remarks <b>Francesc Solé</b>, Spain</p>	
<p>16:00 - 18:00</p>		<p> Workshop III: Cytomorphology</p> <p>Chair: <b>Teresa Vallespí</b>, Spain</p> <p>Welcome <b>Teresa Vallespí</b>, Spain</p> <p>Introduction <b>Jen Goasguen</b>, France</p> <p><b>Workshop objectives:</b></p> <ul style="list-style-type: none"> <li>• Definition of DysE, DysG, DysMeg and Blast Cut-Off</li> <li>• Definition of Blast Cell and Method to Count</li> <li>• Current Classification</li> </ul> <p>Dyserythropoiesis <b>Teresa Vallespí</b>, Spain</p>		

		<p>Dysgranulopoiesis <b>Jean Goasguen</b>, France</p> <p>Dysmegakaryocytopoiesis <b>Ulrich Germing</b>, Germany</p> <p>Blast Cells and How to Count <b>Jean Goasguen</b>, France</p> <p>Introduction to a Clinical Case <b>Ulrich Germing</b>, Germany</p> <p><b>Clinical case:</b></p> <p>Extreme Granulocytic Dysplasia in a de Novo Myelodysplastic Syndrome <i>E. Rodríguez-Arbolí</i>, Sevilla, Spain</p> <p>Final remarks</p>		
18:30 - 20:00	<p>Opening Ceremony</p> <p>Chair: <b>Stephen D. Nimer</b>, USA <b>Guillermo F. Sanz</b>, Spain</p> <p>Introductory Welcome <b>Guillermo F. Sanz</b>, Spain</p> <p>Welcome from the MDS Foundation <b>Stephen D. Nimer</b>, USA</p> <p>Clonal Diversity and Clonal Evolution in MDS Progression <b>Timothy Graubert</b>, USA</p> <p>Tito Bastianello Young Investigator Awards Announcement <b>Stephen D. Nimer</b>, USA</p> <p>Concert Orquesta Filarmónica Martín i Soler de Valencia and Orquesta Unión Musical Santa Cecilia de Onda. Conductor: <b>Carmen Más Arocas</b></p>			
20:00 - 21:30	<b>Welcome Reception</b>			
 Pre-registration and payment required to attend				

**Thursday May 4, 2017**



Time	Sala 1	Sala 2	
08:00-08:30	 <p>Meet the Expert Geriatric Evaluation <b>Reinhard. Stauder</b>, Austria</p>	 <p>Meet the Expert Mesenchymal Cells in MDS <b>Consuelo del Cañizo</b>, Spain</p>	
	Auditorium 1	Auditorium 2	Auditorium 3
08:00 – 09:30	<p>MDS biology and pathogenesis 1</p> <p>Chairs: <b>Rafael Bejar</b>, USA <b>Juan Cruz Cigudosa</b>, Spain</p> <p>MDS: A Stem Cell Disorder <b>Stephen D. Nimer</b>, USA</p> <p>Driver and Late Occurring Somatic Mutations <b>Elli Papaemmanuil</b>, USA</p> <p>Epigenetic Deregulation <b>Maria E Figueroa</b>, USA</p> <p><i>Oral Abstract Presentation:</i> Ancestral Events Including Germline and Somatic Mutations Determine Subclonal Events and Affect Phenotype of Progression in MDS <b>Yasunobu Nagata</b>, USA</p> <p><i>Oral Abstract Presentation:</i> Therapeutic Targeting of MDS AML Stem Cells with An Antisense Inhibitor of STAT3 <b>Aditi Shastri</b>, USA</p>		
09:30-10:00	Coffee Break, Exhibition & Poster Viewing		

<p><b>10:00-11:30</b></p>	<p>MDS biology and pathogenesis 2 Chairs: <b>Benjamin Ebert, USA</b> <b>Stephen D. Nimer, USA</b></p> <p>Aging, CHIP, and MDS <b>David P. Steensma, USA</b></p> <p>The Aberrant Spliceosome Machinery <b>Seishi Ogawa, Japan</b></p> <p>Deregulation of the Innate Immune System <b>Alan F. List, USA</b></p> <p><i>Oral Abstract Presentation:</i> Identification of Aberrant Splicing Events in Myelodysplastic Syndrome Patients with Splicing Factor Gene Mutations <b>Andrea Pellagatti, UK</b></p> <p><i>Oral Abstract Presentation:</i> RNA sequencing reveals TGF Beta Mediated Functional Inhibition of Mesenchymal Stromal Cells in MDS <b>Thomas Schroeder, Germany</b></p>		
<p><b>11:30-13:00</b></p>	<p>Diagnosis and prognosis of MDS / New challenges &amp; new Approaches</p> <p>Chairs: <b>Patricia Font, Spain</b> <b>Guillermo Sanz, Spain</b></p> <p>2016 WHO classification: Main Changes <b>Ulrich Germing, Germany</b></p> <p>Cytogenetics: Still Alive? <b>Francesc Solé, Spain</b></p> <p>Somatic Mutations: A Role for Improving Diagnosis and Risk Assessment? <b>Rafael Bejar, USA</b></p> <p><i>Oral Abstract Presentation:</i> Prognostic Significance of Serial Molecular Annotation in Myelodysplastic Syndromes (MDS) and Secondary Acute Myeloid Leukemia (sAML) <b>David Sallman, USA</b></p> <p><i>Oral Abstract Presentation:</i> Prognostic Value of Early Drop in Platelets in Lower-risk MDS. A Sub-Study from the European LeukemiaNet Lower-Risk MDS (EUMDS) Registry <b>Raphael Itzykson, France</b></p>		

13:00 - 15:00	Lunch Break, Exhibition & Poster Viewing		
15:00 - 16:30	<p>Oral session 1</p> <p>Chairs: <b>Eric Padron, USA</b> <b>Maria E. Diez Campelo, Spain</b></p> <p>Characterization of novel oral splicing modulator, H3B-8800, identifies the mechanistic basis for its preferential lethality towards spliceosome-mutant myeloid malignancy models <b>Silvia Buonamici, USA</b></p> <p>Gain-of-function SAMD9L mutations cause a syndrome of cytopenia, immunodeficiency, myelodysplastic syndrome and neurological symptoms <b>Bianca Tesi, Sweden</b></p> <p>Health-related quality of life is substantially impaired in lower-risk MDS when compared with reference populations and significantly affects overall survival <b>Reinhard Stauder, Austria</b></p> <p>Romiplostim In Low/Int-1-Risk MDS Results in Reduced Bleeding Without Impacting Leukemic Progression: Final Results from A Randomized, Double-Blind, Placebo-Controlled Study <b>Pierre Fenaux, France</b></p> <p>Impact of Gene Mutations on Response to Lenalidomide And Os In Lower-Risk Non-Del(5q) MDS Patients Ineligible/Refractory to Erythropoiesis-Stimulating Agents (Esas) <b>Valeria Santini, Italy</b></p> <p>Cc-486 (Oral Azacitidine) Induces Responses in Patients with Hematological Malignancies Who Had Failed Prior Treatment with Injectable Hypomethylating Agents (Hmas) <b>Guillermo Garcia-Manero, USA</b></p>	<p>13:15-14:45 Industry Supported session not included in the CME/CPD Program</p> <p>Oral session 2</p> <p>Chairs: <b>Benjamin Ebert, USA</b> <b>Jose Cervera, Spain</b></p> <p>Spanish Guidelines for the use of targeted deep sequencing in MDS and CMML <b>Laura Palomo, Spain</b></p> <p>The S100A9-FTO Axis Directs Genetic Instability in Myelodysplastic Syndromes (MDS) <b>Erika Eksioglu, USA</b></p> <p>Novel role of S100A9-induced overexpression of PD-1/PD-L1 in HSPC and MDSC contribute to ineffective hematopoiesis in MDS <b>Sheng Wei, USA</b></p> <p>Persistence of preleukemic clonal hematopoiesis after chemotherapy is associated with poor prognosis in patients with high risk MDS and AML <b>Koichi Takahashi, USA</b></p> <p>A single Next-Generation Sequencing (NGS) assay for the detection of point mutations and large chromosomal abnormalities in MDS patients <b>Alessandro Liquori, Spain</b></p> <p>Distinct genetic alterations in DHX9 and its clinical significance and biological function in the patients with myelodysplastic syndromes <b>Xiao Li, China</b></p>	<p>Nurse Session A</p> <p>Chairs: <b>Inmaculada Vaquero, Spain</b> <b>Petra Lindroos Kølqvist, Sweden</b></p> <p>Health, Technology and Educational Preferences in MDS Patients: Results of An Online Survey <b>Sandra Kurtin, USA</b></p> <p>Home Care for MDS Patients Undergoing Allogeneic Stem Cell Transplantation <b>Nuria Borrás, Spain</b></p> <p>Azacitidine Administration at Home <b>Laura Muñoz, Spain</b></p>
16:30-17:00	Coffee Break, Exhibition & Poster Viewing		

<p><b>17:00-18:30</b></p>	<p>Biology and Management of CMML</p> <p>Chairs:  <b>Eric Padron, USA</b>  <b>Bianca Xicoy, Spain</b></p> <p>Relevance of Flow Cytometry, Cytogenetics, Somatic Mutations, and Epigenetic Alterations in CMML  <b>Eric Solary, France</b></p> <p>Risk Assessment in CMML  <b>Luca Malcovati, Italy</b></p> <p>Current Management and Investigational Approaches  <b>Eric Padron, USA</b></p> <p><i>Oral Abstract Presentation: Hypomethylating Agent Therapy Use and Survival in Older Patients with Chronic myelomonocytic Leukemia in USA: A Large Population-Based Study</i>  <b>Amer Zeidan, USA</b></p> <p><i>Oral Abstract Presentation: MDS With Isolated Trisomy 8: A Type Of MDS Frequently Associated With Myeloproliferative Features? A Report by The Gfm</i>  <b>Louis Drevon, France</b></p>		<p>Nurse Session B</p> <p>Chairs:  <b>Nuria Borrás, Spain</b>  <b>Sandra Kurtin, USA</b></p> <p>Transfusional Support Assessment in MDS  <b>Inmaculada Vaquero, Spain</b></p> <p>Current Treatment of MDS  <b>Joaquín Sánchez-García, Spain</b></p> <p>MDS in Childhood: Special Considerations  <b>Eugenia Trigoso, Spain</b></p> <p>Photovoice For MDS Patients  <b>Petra L. Köllqvist, Sweden</b></p>
<p><b>18:30-19:30</b></p>	<p>Predicting Response to Therapy</p> <p>Chair:  <b>Juan Cruz Cigudosa, Spain</b>  <b>Valeria Santini, Italy</b></p> <p>Prediction of ESAs and Lenalidomide Benefit  <b>Maria E. Díez Campelo, Spain</b></p> <p>Prediction of Azacitidine Benefit  <b>Raphael Itzykson, France</b></p> <p>Predicting Transplantation Outcomes  <b>Matteo G. Della Porta, Italy</b></p>	<p>Health Economics and Outcome Research</p> <p>Chair:  <b>David Bowen, UK</b>  <b>Mikael Sekeres, USA</b></p> <p>Regulatory Aspects and Cost Effectiveness Analysis of Drugs in Europe  <b>David Bowen, UK</b></p> <p>Cost of Care of MDS Patients in USA  <b>Trever Burgon, US</b></p> <p>Patient Reported Outcomes in MDS  <b>Fabio Efficace, Italy</b></p>	
<p><b>19:30-20:30</b></p>			<p>Industry Supported session  not included in the CME/CPD Program</p>

**Friday May 5, 2017**

Friday May 5, 2017				
Time	Sala 8	Sala 9		
08:00-08:30	 Meet the Expert The Future of Genomics in MDS: What Will We Require for Our Clinical Daily Practice? <b>Jaroslav Maciejewski</b> , USA	 Meet the Expert Treatment After Failure of Hypomethylating Agents? <b>Lionel Ades</b> , France		
Time	Auditorium 1	Auditorium 2	Auditorium 3	Patient Forum at Auditorium Hospital Universitari i Politécnic La Fe
08:30 - 10:00	Singular subtypes of MDS  Chairs: <b>Aristoteles Giagounidis</b> , Germany <b>Joaquín Sánchez-García</b> , Spain  Insights into the mechanism of action of lenalidomide in patients with deletion 5q <b>Benjamin Ebert</b> , USA  Clonal evolution in aplastic anemia and hypoplastic MDS <b>Ghulam J. Mufti</b> , UK  New developments in childhood MDS <b>Charlotte M. Niemeyer</b> , Germany  <i>Oral Abstract Presentation:</i> Genome-Wide Dna Methylation Profiling Reveals Distinct Molecular Subgroups of Juvenile Myelomonocytic Leukemia with Clinical Significance			



	<p><b>Christian Fiotho, Germany</b></p> <p><i>Oral Abstract Presentation:</i>  TET2 Is Iron-Dependent So Its Activity May Be Compromised in SF3B1 Mutated Age-Related Clonal Hematopoiesis of Indeterminate Potential  <b>Tomas Radivoyevitch, USA</b></p>			
<p><b>10:00 - 10:30</b></p>	<p>Coffee Break, Exhibition &amp; Poster Viewing</p>			
<p><b>10:30 - 12:00</b></p>	<p>Therapy-1 Current options</p> <p>Chairs:  <b>Teresa Bernal, Spain</b>  <b>Uwe Platzbecker, Germany</b></p> <p>How I treat MDS patients?  <b>Pierre Fenaux, France</b></p> <p>Management of MDS with 5q- after lenalidomide failure  <b>Aristoteles Giagounidis, Germany</b></p> <p>Looking for the best partner for hypomethylating gents in higher-risk patients  <b>Mikael Sekeres, USA</b></p> <p><i>Oral Abstract Presentation:</i>  Challenging Iwg2006 Response Criteria: Results of A Randomized Study of Epoetin Alfa Versus Placebo in Anemic Lower Risk MDS Patients  <b>Pierre Fenaux, France</b></p> <p><i>Oral Abstract Presentation:</i>  Eltrombopag In Combination with Azacitidine For First-Line Treatment of MDS Patients with Thrombocytopenia: The Randomized, Placebo-Controlled, Phase Iii, Support Study  <b>Michael Dickinson, Australia</b></p>			

<p><b>12:00 - 13:30</b></p>	<p>Therapy-2 New developments</p> <p>Chairs:  <b>Maria E. Diez Campelo</b>, Spain  <b>Alan F. List</b>, USA</p> <p>Clinical trials in Europe  <b>Lionel Ades</b>, France</p> <p>Clinical trials in USA  <b>Guillermo García-Manero</b>, USA</p> <p>New agents for anemic patients: modified activin receptors  <b>Uwe Platzbecker</b>, Germany</p> <p><i>Oral Abstract Presentation:</i>  Enasidenib (Ag-221), A Selective Oral Inhibitor of Mutant Isocitrate Dehydrogenase 2 (Idh2) Enzyme, In Patients with Myelodysplastic Syndromes (MDS)  <b>Eytan M. Stein</b>, USA</p> <p><i>Oral Abstract Presentation:</i>  Updated results from Phase 2 Study of Guadecitabine for Patients with Untreated Int-2/High Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia  <b>Guillermo Montalban-Bravo</b>, USA</p>			
<p><b>13:30 – 15:00</b></p>	<p>13:45-14:45  Industry Supported session  not included in the CME/CPD Program</p>	<p>Lunch Break, Exhibition &amp; Poster Viewing</p>	<p>Lunch Break, Exhibition &amp; Poster Viewing</p>	

<p><b>15:00-16:30</b></p>	<p>Therapy-3 Allogeneic hematopoietic cell transplantation</p> <p>Chairs: <b>Theo de Witte</b>, The Netherlands <b>Jaimie Sanz Caballer</b>, Spain</p> <p>Candidates and timing <b>Theo de Witte</b>, The Netherlands</p> <p>Pre- and post-transplant strategies to reduce relapse <b>Charles Craddock</b>, UK</p> <p>New stem cell donor sources and regimens for transplantation <b>David Valcarcel</b>, Spain</p> <p><i>Oral Abstract Presentation:</i> Allogeneic hematopoietic stem cell transplantation for patients aged 60 years or older with myelodysplastic syndrome in Japan <b>Hidehiro Itonaga</b>, Japan</p> <p><i>Oral Abstract Presentation:</i> Chronic Gvhd Could Ameliorate the Impact of Adverse Somatic Mutations in Patients with Myelodysplastic Syndromes and Hematopoietic Stem Cell Transplantation <b>Juan Carlos Cabakkero</b>, Spain</p>		<p>Pharmacist Session A What a pharmacist should know about MDS?</p> <p>Chairs: <b>Albert Asunción</b>, Spain</p> <p>Diagnosis and evaluation of response <b>Guillermo Sanz</b>, Spain</p> <p>Treatment of higher-risk MDS patients <b>Hannah Kershaw</b>, UK</p> <p>Treatment of lower-risk MDS patients <b>Garbiñe Lizeaga</b>, Spain</p>	<p>PATIENT FORUM</p> <p>Chairs: <b>Andrés Jerez</b>, Spain <b>Begoña Barragán</b>, Spain</p> <p>Patient Arrival and Registration Registro de asistentes</p> <p>Welcome and presentation Bienvenida – Introducción a la jornada <b>Andrés Jerez</b>, Spain</p> <p>The MDS Foundation’s Building Blocks of Hope: Quick Tips for Patients and Caregivers</p> <p>Consejos breves para pacientes y cuidadores: Programa “Dando paso a la esperanza” de la MDS Foundation. <b>Andrés Jerez</b>, Spain</p>
				<p>Emotional and social impact of myelodysplastic syndromes: recommendations for patients and relatives</p> <p>Impacto emocional y social de los Síndromes Mielodisplásicos: recomendaciones para pacientes y familiares <b>Miguel Rojas Cásares</b>, Spain</p>
<p><b>16:30-17:00</b></p>	<p>Coffee Break, Exhibition &amp; Poster Viewing</p>			

<p><b>17:00 – 18:15</b></p>	<p>Caring for the patient with MDS</p> <p>Chairs:  <b>Santiago Bonanad</b>, Spain  <b>Reinhard Stauder</b>, Austria</p> <p>Iron overload in MDS. Is there something new?  <b>Norbert Gattermann</b>, Germany</p> <p>Thrombocytopenia in MDS  <b>Valeria Santini</b>, Italy</p> <p>Comorbidity index and comprehensive geriatric assessment in treatment decision  <b>Fernando Ramos</b>, Spain</p>	<p>Controversial issues in MDS</p> <p>Chairs:  <b>Lourdes Florensa</b>, Spain  <b>Torsten Haferlach</b>, Germany</p> <p>How do I diagnose MDS using currently available tools?  <b>Torsten Haferlach</b>, Germany</p> <p>Choosing the appropriate denominator for counting BM blasts  <b>Leonor Arenillas</b>, Spain</p> <p>Do all MDS subtypes reduce life expectancy?  <b>Arturo Pereira</b>, Spain</p>	<p>Pharmacist Session B  Hematologic geriatric patients</p> <p>Chairs:  <b>Amparo Burgos</b>, Spain</p> <p>Geriatric assessment and multidisciplinary teams.  <b>Raúl Córdoba</b>, Spain</p> <p>Pharmacists role in hematologic geriatric patients  <b>Estela Moreno</b>, Spain</p>	<p>New Therapies and Patient Treatment Options  Nuevas opciones y estrategias de tratamiento en SMD  <b>Guillermo García-Manero</b>, USA</p> <p>Round-table Q&amp;A</p> <p>Mesa Redonda y foro debate con asistentes.  <b>Guillermo García-Manero</b>, USA  <b>Miguel Rojas Cásares</b>, Spain</p>
<p><b>18:00-19:15</b></p>	<p>Guided Poster Session</p> <p>Chairs:  <b>Eva Hellström-Lindberg</b>, Sweden  <b>Jaroslav Maciejewski</b>, USA  <b>Moshe Mittelman</b>, Israel  <b>Elli Papaemmanuil</b>, USA</p> <p><b>Clinical studies</b>  (6 posters already selected for discussion)</p> <p><b>Biological &amp; Research studies</b>  (6 posters already selected for discussion)</p> <p><b>Clinical Cases</b>  (6 invited posters)</p>			
<p><b>20:30 - 23:00</b></p>	<p><b>Networking Event</b></p>			

## Saturday May 6, 2017

Time	Auditorium 1	Auditorium 2	Auditorium 3
08:30 - 10:00	<p style="text-align: center;">Oral session 3</p> <p style="text-align: center;">Chairs: <b>Michael Savona</b>, USA <b>David Valcarcel</b>, Spain</p> <p style="text-align: center;">A Phase 3 Randomized Placebo (Pbo)-Controlled Double-Blind Trial of Darbepoetin Alfa in Low or Intermediate-1 (Int-1) Risk Myelodysplastic Syndromes (MDS) <b>Uwe Platzbecker</b>, Germany</p> <p style="text-align: center;">Combination of Oral Rigosertib And Injectable Azacitidine In Patients with Myelodysplastic Syndromes (MDS) <b>Shyamala Navada</b>, USA</p> <p style="text-align: center;">A Retrospective Validation of International Consortium for MDS/MPN Response Criteria in CMML Treated with Hypomethylating Agents <b>Matthieu Duchmann</b>, France</p> <p style="text-align: center;">Luspatercept Response in New Subpopulations of Patients with Lower-Risk Myelodysplastic Syndromes (MDS): Update of the PACE Study <b>Uwe Platzbecker</b>, USA</p> <p style="text-align: center;">Robust Patient-Derived Xenografts (Pdx) Capture the Disease Fidelity of Chronic Myelomonocytic Leukemia (CMML) and Juvenile Myelomonocytic Leukemia (JMML) <b>Eric Padron</b>, USA</p> <p style="text-align: center;">Phase 2 study of selinexor in patients with myelodysplastic syndromes refractory to hypomethylating agents: Interim report <b>Virginia M. Klimek</b>, USA</p>	<p style="text-align: center;">Oral session 4</p> <p style="text-align: center;">Chairs: <b>Peter L. Greenberg</b>, USA <b>Francesc Solé</b>, Spain</p> <p style="text-align: center;">Chromosomal aberrations in therapy-related myelodysplastic syndromes - relations to primary disease, therapy and prognostic significance <b>Meritxell Nomdedeu</b>, Spain</p> <p style="text-align: center;">Outcome of Lower-Risk Patients with Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis Stimulating Agents- <b>Sophie Park</b>, France</p> <p style="text-align: center;">Adding Molecular Data to Prognostic Models can improve its Predictive Power in Treated Patients with Myelodysplastic Syndromes (MDS) <b>Aziz Nazha</b>, USA</p> <p style="text-align: center;">Dual deficiency of miR-146a and miR-145 in an age-related inflammatory bone marrow microenvironment induces ineffective erythropoiesis that phenocopies del(5q) MDS <b>Peng Ji</b>, USA</p> <p style="text-align: center;">Identification of The Specific Hematopoietic Stem Cell Populations Responsible for Failure to Hypomethylating Agents in Myelodysplastic Syndromes <b>Irene Ganan-Gomez</b>, USA</p> <p style="text-align: center;">Autophagy Stimulation Improves Erythroid Proliferative Capacity in Models of SF3B1 Mutant MDS <b>Valeria Visconte</b>, USA</p>	
10:00 - 10:30	Coffee Break		
10:30 - 12:00	<p style="text-align: center;">Tito Bastianello and MDS Foundation Young Investigators Award</p> <p style="text-align: center;">Chairs: <b>Guillermo Sanz</b> <b>Stephen D. Nimer</b> <b>Lars Kjeldsen</b></p>		

	<p>HIF1A signaling is a central pathobiologic mediator of MDS  <b>Yoshihiro Hayashi, USA</b></p> <p>An Analysis of The Transcriptional Response of Myelodysplastic Syndrome Stem Cells to Therapy at Single-Cell Resolution  <b>Stephen Chung, USA</b></p> <p>Mutational signature and clonal architecture of low risk Myelodysplastic Syndromes with del(5q)  <b>Vera Adema, USA</b></p> <p>Labile Plasma Iron predicts for survival in patients undergoing allogeneic stemcell-transplantation – results from the prospective multicenter German-Austrian ALLIVE trial  <b>Martin Wermke, Germany</b></p> <p>MDS Foundation Young Investigators Award Announcement  <b>David Sallman, USA</b>  <b>Yoshihiro Hayashi, USA</b></p>		
<p><b>12:00 - 12:30</b></p>	<p>Closing remarks and farewell</p> <p>Chair:  <b>Guillermo Sanz, Spain</b>  <b>Stephen D. Nimer, USA</b></p> <p>Announcement of the 15th International Symposium on MDS, Copenhagen, 2019  <b>Lars Kjeldsen, Denmark</b>  <b>Kirsten Grønbaek, Denmark</b></p> <p>Closing Remarks &amp; Farewell  <b>Guillermo Sanz, Spain</b>  <b>Stephen D. Nimer, USA</b></p>		